Middle East & Africa Asparaginase Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Escherichia coli, Erwinia chrysanthemi, Pegylated, and Others), Application (Therapeutic, Food Processing, and Others), and End-use Industry (Heal

Middle East & Africa Asparaginase Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Escherichia coli, Erwinia chrysanthemi, Pegylated, and Others), Application (Therapeutic, Food Processing, and Others), and End-use Industry (Healthcare and Food Manufacturing) 

The MEA asparaginase market is expected to grow from US$ 22.60 million in 2022 to US$ 48.37 million by 2028; it is estimated to grow at a CAGR of 13.5% from 2022 to 2028.

New Product Launches and Approvals

The pharmaceutical & food industries are constantly developing at a significant rate due to the rising demand from a large population. The industries have increased new product development, product launches, and approvals across the MEA. Additionally, major market players are involved in research and development activities to ensure the innovation and development of efficient products. In recent years, the market is experiencing various developments, such as product launches and approvals, which are likely to create ample opportunities in the market. For instance, In July 2021, Ligand Pharmaceuticals Incorporated partnered with Jazz Pharmaceuticals Plc to launch Rylaze [asparaginase E. chrysanthemi (recombinant)-rywn], also known as JZP458. Rylaze is a recombinant Erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for treating acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month or older) who have developed hypersensitivity to E. coli-derived asparaginase. Similarly, in August 2020, Lonza expanded microbial capacity and extended a long-term partnership with Servier Pharmaceuticals, Inc. for l-asparaginase API manufacturing. The new facility will provide mid-scale commercial manufacturing to multiple customers and serve the growing needs of Servier, an independent international pharmaceutical company and long-term Lonza partner. Thus, the increase in new product development, launches, and other strategic collaborations among market players are likely to create ample opportunities for the asparaginase market growth in the coming years.

Market Overview



The MEA asparaginase market is segmented into the UAE, Saudi Arabia, South Africa, and Rest of MEA. Saudi Arabia dominated the market in 2022. Saudi Arabia is one of the important countries in the MEA that has significant scope for the cancer treatment market. The healthcare system in the country is developing at a rapid pace and an increasing number of international companies are developing medical and research teams in the country. Also, a sharp increase in the state health budget is expected to drive the demand for cancer drugs in the country. Saudi Arabia has a huge population base who suffer from cancer. As per the data of WHO, in 2020, approximately 27,885 new cases of cancer were registered in the country, including ~1,698 non-Hodgkin lymphoma (NHL) cases and 1,676 cases of leukemia. Moreover, a study published by King Abdul-Aziz City for Science and Technology (KACST) demonstrated that the marine environment of the Red Sea has the potential to be a potent source of bacterial strains for the discovery of anticancer drugs. The identification of strains with improved ASNase yields has attracted significant attention to improve the cost-effectiveness of these enzymes. Thus, above-mentioned factors are expected to drive the growth of asparaginase market in the coming years in the country.

MEA Asparaginase Market Revenue and Forecast to 2028 (US$ Million)

MEA Asparaginase Market Segmentation

The MEA asparaginase market is segmented based on type, application, end-use industry, and country.

Based on type, the MEA asparaginase market is segmented into escherichia coli, erwinia chrysanthemi, pegylated, and others. The escherichia coli segment held the largest market share in 2022. Based on application, the MEA asparaginase market is segmented into therapeutic, food processing, and others. The therapeutic segment held the largest market share in 2022. The therapeutic segment is further classified into acute lymphoblastic leukemia, lymphoblastic lymphoma, and others. Based on end-use industry, the MEA asparaginase market is bifurcated into healthcare and food manufacturing. The healthcare segment held the larger market share in 2022. Based on country, the MEA asparaginase market has been categorized into the UAE, Saudi Arabia, South Africa, and rest of MEA. Our regional analysis states that Saudi Arabia dominated the market in 2022. Biovendor, LLC; Creative Enzymes; Jazz Pharmaceuticals, Inc.; medac GMBH; Servier Pharmaceuticals LLC; Taj Pharmaceuticals Limited; and United Biotech (P) Limited are the leading companies operating in the MEA asparaginase market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA asparaginase market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA asparaginase market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the asparaginase market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution